New anti-inflammatory targets for chronic obstructive pulmonary disease

Nature Reviews Drug Discovery

Volumn 12, Issue 7, 2013, Pages 543-559

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADZ 4818; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AZ 9668; BARDOXOLONE; CANAKINUMAB; CHEMOKINE RECEPTOR ANTAGONIST; CORTICOSTEROID; CYTOKINE; ELUBRIXIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; GSK 256066; INFLAMMASOME; INFLIXIMAB; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NAVARIXIN; NORTRIPTYLINE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PROTEINASE INHIBITOR; ROFLUMILAST; RPL 554; SD 282; SETILEUTON; SULFORAPHANE; THEOPHYLLINE; TPI 1100; UK 500001; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZILEUTON;

ANTIINFLAMMATORY ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIARRHEA; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; EPIGENETICS; HEART ARRHYTHMIA; HUMAN; IMMUNE RESPONSE; INFLAMMATION; KIDNEY DISEASE; LOW DRUG DOSE; LUNG CANCER; LUNG EMPHYSEMA; LUNG INJURY; NAUSEA; NONHUMAN; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEIZURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR TARGETED THERAPY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84879693217     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4025     Document Type: Review

References (158)

1. Barnes, P. J. Chronic obstructive pulmonary disease: a growing but neglected epidemic. PLoS Med. 4, e112 (2007).
2. Gershon, A. S., Warner, L., Cascagnette, P., Victor, J. C. & To, T. Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. Lancet 378, 991-996 (2011).
3. Mannino, D. M. & Buist, A. S. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 370, 765-773 (2007). (Pubitemid 47321908)
4. Salvi, S. S. & Barnes, P. J. Chronic obstructive pulmonary disease in non-smokers. Lancet 374, 733-743 (2009).
5. Barnes, P. J. Chronic obstructive pulmonary disease: effects beyond the lungs. PLoS Med. 7, e1000220 (2010).
6. Vestbo, J. et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD Executive Summary. Am. J. Respir. Crit. Care Med. 187, 347-365 (2013).
7. Matera, M. G., Page, C. P. & Cazzola, M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol. Sci. 32, 495-506 (2011).
8. Barnes, P. J. Inhaled corticosteroids in COPD: a controversy. Respiration 80, 89-95 (2010).
9. Calverley, P. M. et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374, 685-694 (2009).
10. Ito, K. et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med. 352, 1967-1976 (2005). (Pubitemid 40638367)
11. Hogg, J. C. et al. The nature of small-Airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 350, 2645-2653 (2004). (Pubitemid 38787999)
12. McDonough, J. E. et al. Small-Airway obstruction and emphysema in chronic obstructive pulmonary disease. N. Engl. J. Med. 365, 1567-1575 (2011).
13. + T cells in COPD have increased expression of bacterial TLRs. Respir. Res. 14, 13 2013).
14. + T cells in chronic obstructive pulmonary disease. Respir. Res. 12, 149 (2011).
15. Vassallo, R. et al. Cigarette smoke promotes dendritic cell accumulation in COPD; a Lung Tissue Research Consortium study. Respir. Res. 11, 45 (2010).
16. Majo, J. et al. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur. Respir. J. 17, 946-953 (2001). (Pubitemid 32600344)
17. Di Stefano, A. et al. Th17-related cytokine expression is increased in the bronchial mucosa of stable COPD patients. Clin. Exp. Immunol. 157, 316-324 (2009).
18. Pridgeon, C. et al. Regulation of IL-17 in chronic inflammation in the human lung. Clin. Sci. 120, 515-524 (2011).
19. Taylor, A. E. et al. Defective macrophage phagocytosis of bacteria in COPD. Eur. Respir. J. 35, 1039-1047 (2010).
20. Karayama, M. et al. Antiendothelial cell antibodies in patients with COPD. Chest 138, 1303-1308 (2010).
21. Kirkham, P. A. et al. Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 184, 796-802 (2011).
22. Papi, A. et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 173, 1114-1121 (2006). (Pubitemid 43726892)
23. Nakamaru, Y. et al. A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J. 23, 2810-2819 (2009).
24. Rennard, S. I. et al. The safety and efficacy of infliximab in moderate-to-severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 175, 926-934 (2007). (Pubitemid 46684703)
25. Barnes, P. J. The cytokine network in COPD. Am. J. Respir. Cell. Mol. Biol. 41, 631-638 (2009).
26. Bafadhel, M. et al. Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease. Respiration 83, 36-44 (2012).
27. Strowig, T., Henao-Mejia, J., Elinav, E. & Flavell, R. Inflammasomes in health and disease. Nature 481, 278-286 (2012).
28. Zhang, H. Anti-IL-1β therapies. Recent Pat. DNA Gene Seq. 5, 126-135 (2011).
29. Rovina, N. et al. Interleukin-18 in induced sputum: association with lung function in chronic obstructive pulmonary disease. Respir. Med. 103, 1056-1062 (2009).
30. Lommatzsch, M. et al. Extracellular adenosine tri-phosphate and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 181, 928-934 (2010).
31. Boxer, M. B., Shen, M., Auld, D. S., Wells, J. A. & Thomas, C. J. A small molecule inhibitor of caspase 1. Probe Reports from the NIH Molecular Libraries Program [online], http://www.ncbi.nlm.nih.gov/books/NBK56241 (National Center for Biotechnology Information, 2010).
32. Lucattelli, M. et al. P2X7 receptor signaling in the pathogenesis of smoke-induced lung inflammation and emphysema. Am. J. Respir. Cell. Mol. Biol. 44, 423-429 (2011).
33. Gonsiorek, W. et al. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J. Pharmacol. Exp. Ther. 322, 477-485 (2007). (Pubitemid 47105793)
34. Holz, O. et al. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur. Respir. J. 35, 564-570 (2010).
35. Lazaar, A. L. et al. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br. J. Clin. Pharmacol. 72, 282-293 (2011).
36. Magnussen, H. et al. Safety and efficacy of SCH527123, a novel CXCR2 antagonist, in patients with COPD. Eur. Resp. J. 36, 38S (2010).
37. Donnelly, L. E. & Barnes, P. J. Chemokine receptor CXCR2 antagonism to prevent airway inflammation. Drugs Future 36, 465-472 (2011).
38. Gaggar, A. et al. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J. Immunol. 180, 5662-5669 (2008).
39. Xu, X. et al. A self-propagating matrix metalloprotease-9 (MMP-9) dependent cycle of chronic neutrophilic inflammation. PLoS ONE 6, e15781 (2011).
40. Traves, S. et al. Elevated levels of the chemokines GROα and MCP-1 in sputum samples from COPD patients. Thorax 57, 590-595 (2002). (Pubitemid 34761760)
41. Costa, C. et al. CXCR3 and CCR5 chemokines in the induced sputum from patients with COPD. Chest 133, 26-33 (2008).
42. Kerstjens, H. A., Bjermer, L., Eriksson, L., Dahlstrom, K. & Vestbo, J. Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients. Respir. Med. 104, 1297-1303 (2010).
43. Groutas, W. C., Dou, D. & Alliston, K. R. Neutrophil elastase inhibitors. Expert Opin. Ther. Pat. 21, 339-354 (2011).
44. Stevens, T. et al. AZD9668: pharmacological characterization of a novel oral inhibitor of neutrophil elastase. J. Pharmacol. Exp. Ther. 339, 313-320 (2011).
45. Kuna, P., Jenkins, M., O'Brien, C. D. & Fahy, W. A. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD. Respir. Med. 106, 531-539 (2011).
46. Vogelmeier, C., Aquino, T. O., O'Brien, C. D., Perrett, J. & Gunawardena, K. A. A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium. COPD 9, 111-120 (2012).
47. Churg, A. et al. Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. Thorax 62, 706-713 (2007). (Pubitemid 47235016)
48. Kirkham, P. A. & Barnes, P. J. Oxidative stress in COPD. Chest (in the press).
49. Montuschi, P. et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Respir. Crit. Care Med. 162, 1175-1177 (2000).
50. Rahman, I. et al. 4-hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 166, 490-495 (2002).
51. Caramori, G. et al. Unbalanced oxidant-induced DNA damage and repair in COPD: a link towards lung cancer. Thorax 66, 521-527 (2011).
52. Tomita, K., Barnes, P. J. & Adcock, I. M. The effect of oxidative stress on histone acetylation and IL-8 release. Biochem. Biophys. Res. Comm. 301, 572-577 (2003). (Pubitemid 36279279)
53. Malhotra, D. et al. Decline in NRF2 regulated antioxidants in COPD lungs due to loss of its positive regulator DJ-1. Am. J. Respir. Crit. Care Med. 178, 592-604 (2008).
54. Mercado, N. et al. Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochem. Biophys. Res. Commun. 406, 292-298 (2011).
55. Malhotra, D. et al. Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients. J. Clin. Invest. 121, 4289-4302 (2011).
56. Sussan, T. E. et al. Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proc. Natl Acad. Sci. USA 106, 250-255 (2009).
57. Rossing, P. Diabetic nephropathy: could problems with bardoxolone methyl have been predicted? Nature Rev. Nephrol. 9, 128-130 (2013).
58. Gold, R. et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 367, 1098-1107 (2012).
59. Keatings, V. M., Jatakanon, A., Worsdell, Y. M. & Barnes, P. J. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am. J. Respir. Crit. Care Med. 155, 542-548 (1997). (Pubitemid 27085799)
60. Culpitt, S. V., Nightingale, J. A. & Barnes, P. J. Effect of high dose inhaled steroid on cells, cytokines and proteases in induced sputum in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 160, 1635-1639 (1999).
61. Loppow, D. et al. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir. Med. 95, 115-121 (2001). (Pubitemid 32624442)
62. Francis, S. H., Houslay, M. D. & Conti, M. Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action. Handb. Exp. Pharmacol. 47-84 (2011).
63. Hatzelmann, A. et al. The preclinical pharmacology of roflumilast - a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 23, 235-256 (2010).
64. Vestbo, J., Tan, L., Atkinson, G. & Ward, J. A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Eur. Respir. J. 33, 1039-1044 (2009).
65. Nials, A. T. et al. In vivo characterization of GSK256066, a high-Affinity inhaled phosphodiesterase 4 inhibitor. J. Pharmacol. Exp. Ther. 337, 137-144 (2011).
66. Naganuma, K. et al. Discovery of selective PDE4B inhibitors. Bioorg. Med. Chem. Lett. 19, 3174-3176 (2009).
67. + T-lymphocytes. Mol. Pharmacol. 66, 1679-1689 (2004). (Pubitemid 39564796)
68. Fortin, M. et al. A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice. Respir. Res. 10, 39 (2009).
69. Boswell-Smith, V. et al. The pharmacology of two novel long-Acting phosphodiesterase 3/4 inhibitors, RPL554 [9, 10-dimethoxy-2(2, 4, 6-trimethylphenylimino)-3-(n-carbamoyl-2-Aminoethyl)-3, 4, 6, 7-tetrahydro-2H-pyrimido[6, 1-A]isoquinolin-4-one] and RPL565 [6, 7-dihydro-2-(2, 6-diisopropylphenoxy)-9, 10-dimethoxy-4H-pyrimido[6, 1-A]isoquino lin-4-one]. J. Pharmacol. Exp. Ther. 318, 840-848 (2006).
70. Belkina, A. C, Nikolajczyk, B. S. & Denis, G. V. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J. Immunol. 190, 3670-3678 (2013).
71. Kruidenier, L. et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488, 404-408 (2012).
72. Renda, T. et al. Increased activation of p38 MAPK in COPD. Eur. Respir. J. 31, 62-69 (2008).
73. Smith, S. J. et al. Inhibitory effect of p38 mitogen-Activated protein kinase inhibitors on cytokine release from human macrophages. Br. J. Pharmacol. 149, 393-404 (2006). (Pubitemid 44582246)
74. Medicherla, S. et al. p38a selective MAP kinase inhibitor, SD-282, reduces inflammation in a sub-chronic model of tobacco smoke-induced airway inflammation. J. Pharmacol. Exp.Ther. 324, 921-929 (2007). (Pubitemid 351397845)
75. Hammaker, D. & Firestein, G. S. "Go upstream, young man": lessons learned from the p38 saga. Ann. Rheum. Dis. 69 (Suppl. 1), i77-i82 (2010).
76. Lomas, D. A. et al. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J. Clin. Pharmacol. 52, 416-424 (2011).
77. Duan, W. et al. Inhaled p38a mitogen-Activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am. J. Respir. Crit. Care Med. 171, 571-578 (2005). (Pubitemid 40365411)
78. Millan D. S. et al. Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. J. Med. Chem. 54, 7797-7814 (2011).
79. Lee, Y. C. et al. TRX-ASK1-JNK signaling regulation of cell density-dependent cytotoxicity in cigarette smoke-exposed human bronchial epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 294, L92 1-L931 (2008).
80. Marwick, J. A., Chung, K. F. & Adcock, I. M. Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease. Ther. Adv. Respir. Dis. 4, 19-34 (2010).
81. To, Y. et al. Targeting phosphoinositide-3-kinase-ô with theophylline reverses corticosteroid insensitivity in COPD. Am. J. Resp. Crit. Care Med. 182, 897-904 (2010).
82. Gustafson, A. M. et al. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci. Transl. Med. 2, 26ra25 (2010).
83. Medina-Tato, D. A., Ward, S. G. & Watson, M. L. Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond. Immunology 121, 448-461 (2007). (Pubitemid 47030097)
84. Doukas, J. et al. Aerosolized phosphoinositide 3-kinase y/ô inhibitor TG100-115 [3-[2, 4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J. Pharmacol. Exp. Ther. 328, 758-765 (2009).
85. Marwick, J. A. et al. Inhibition of PI3KÔ restores glucocorticoid function in smoking-induced airway inflammation in mice. Am. J. Respir. Crit. Care Med. 179, 542-548 (2009).
86. Culpitt S. V. et al. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 167, 24-31 (2003). (Pubitemid 36015913)
87. Ito, K. et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-KB suppression. J. Exp. Med. 203, 7-13 (2006). (Pubitemid 43139638)
88. Cosio, B. G. et al. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J. Exp. Med. 200, 689-695 (2004). (Pubitemid 39258317)
89. Ford, P. A. et al. Treatment effects of low dose theophylline combined with an inhaled corticosteroid in COPD. Chest 137, 1338-1344 (2010).
90. Mercado, N., To, Y, Ito, K. & Barnes, P. J. Nortriptyline reverses corticosteroid insensitivity by inhibition of PI3K-Ô. J. Pharmacol. Exp. Ther. 337, 465-470 (2011).
91. Meja, K. K. et al. Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2. Am. J. Respir. Cell. Mol. Biol 39, 312-323 (2008).
92. Kobayashi, H. et al. A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition. Br. J. Pharmacol. 21 Mar 2013 (doi:10.1111/bph.12187).
93. Garcha, D. S. et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 67, 1075-1080 (2012).
94. Sethi, S. et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir. Res. 11, 10 (2010).
95. Wilson R. et al. Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a Phase II randomised study. Eur. Respir. J. 41, 1107-1115 (2012).
96. Ong H. X. et al. Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia. Pharm. Res. 29, 3335-3346 (2012).
97. Seemungal, T. A. et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am. J. Respir. Crit. Care Med. 178, 1139-1147 (2008).
98. Albert, R. K. et al. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 365, 689-698 (2011).
99. Kobayashi, Y H. et al. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-KB inhibition. J. Pharmacol. Exp. Ther. 345, 76-84 (2013).
100. Sugawara, A. et al. Novel 12-membered non-Antibiotic macrolides from erythromycin A; EM900 series as novel leads for anti-inflammatory and/or immunomodulatory agents. Bioorg. Med. Chem. Lett. 21, 3373-3376 (2011).
101. Richens, T. R. et al. Cigarette smoke impairs clearance of apoptotic cells through oxidant-dependent activation of RhoA. Am. J. Respir. Crit. Care Med. 179, 1011-102 1 (2009).
102. Hodge, S. & Reynolds, P. N. Low-dose azithromycin improves phagocytosis of bacteria by both alveolar and monocyte-derived macrophages in chronic obstructive pulmonary disease subjects. Respirology 17, 802-807 (2012).
103. Serhan, C. N. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am. J. Pathol. 177, 1576-1591 (2010).
104. Serhan, C. N. Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J. 26, 1755-1765 (2012).
105. Hind, M., Gilthorpe, A., Stinchcombe, S. & Maden, M. Retinoid induction of alveolar regeneration: from mice to man? Thorax 64, 451-457 (2009).
106. Roth, M. D. et al. Feasibility of retinoids for the treatment of emphysema study. Chest 130, 1334-1345 (2006). (Pubitemid 44786724)
107. Stolk, J. et al. Randomized controlled trial for emphysema with a selective agonist of the gamma type retinoic acid receptor. Eur. Respir. J. 40, 306-312 (2012).
108. Hegab, A. E. et al. Intranasal HGF administration ameliorates the physiologic and morphologic changes in lung emphysema. Mol. Ther. 16, 1417-1426 (2008).
109. Wilkinson J. E. et al. Rapamycin slows aging in mice. Aging Cell 11, 675-682 (2012).
110. Anisimov L. M. et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle 7, 2769-2773 (2008).
111. Donnelly, L. E. et al. Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am. J. Physiol. Lung Cell Mol. Physiol 287, L774-L783 (2004). (Pubitemid 39249390)
112. 1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 158, 1951-1957 (1998). (Pubitemid 29008838)
113. Sime, P. J. The antifibrogenic potential of PPARy ligands in pulmonary fibrosis. J. Investig. Med. 56, 534-538 (2008).
114. Fonseca, C, Abraham, D. & Renzoni, E. A. Endothelin in pulmonary fibrosis. Am. J. Respir. Cell. Mol. Biol 44, 1-10 (2011).
115. DAlessandro-Gabazza, C. N. et al. Development and preclinical efficacy of novel transforming growth factor-beta1 short interfering RNAs for pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 46, 397-406 (2012).
116. Siedlinski, M. et al. Dissecting direct and indirect genetic effects on chronic obstructive pulmonary disease (COPD) susceptibility. Hum. Genet. 132, 431-441 (2011).
117. Hansel, T. T. & Barnes, P. J. New drugs for exacerbations of chronic obstructive pulmonary disease. Lancet 374, 744-755 (2009).
118. Galban CJ et al. Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nature Med. 18, 1711-1715 (2012).
119. Agusti, A. et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE 7, e37483 (2012).
120. Lee, J. H. et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am. J. Respir. Crit. Care Med. 172, 987-993 (2005).
121. Burgel P. R. et al. Tw o distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality. PLoS ONE 7, e51048 (2012).
122. Siva R. et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur. Respir. J. 29, 906-913 (2007). (Pubitemid 46711894)
123. Celli B. R. et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 185, 1065-1072 (2012).
124. Mancini, G. B. et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J. Am. Coll. Cardiol. 47, 2554-2560 (2006). (Pubitemid 43866389)
125. Bauer C. M. et al. Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection. PLoS ONE 5, e13251 (2010).
126. Hicks, A., Monkarsh, S. P., Hoffman, A. F. & Goodnow, R. Jr. Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments. Expert Opin. Investig. Drugs 16, 1909-1920 (2007). (Pubitemid 351403723)
127. Barnes, P. J. et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 174, 6-14 (2006). (Pubitemid 43955238)
128. Woodruff, P. G. et al. Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization. COPD 8, 21-29 (2011).
129. Gronke, L. et al. Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 21, 409-417 (2008). (Pubitemid 351312685)
130. Bernstein, J. A. et al. MK-0633, a potent 5-lipoxy-genase inhibitor, in chronic obstructive pulmonary disease. Respir. Med. 105, 392-401 (2011).
131. Dentener, M. A. et al. Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: a pilot study. Respiration 76, 275-282 (2008).
132. Dhimolea, E. Canakinumab. MAbs 2, 3-13 (2010).
133. Strand, V. et al. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology 51, 1860-1869 (2012).
134. Mahler, D. A., Huang, S., Tabrizi, M. & Bell, G. M. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 126, 926-934 (2004). (Pubitemid 39258050)
135. Doe, C. et al. Expression of the T helper 17-Associated cytokines IL-17A and IL-17F in asthma and COPD. Chest 138, 1140-1147 (2010).
136. Leonardi, C. et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366, 1190-1199 (2012).
137. Papp, K. A. et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366, 1181-1189 (2012).
138. Benson, J. M. et al. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nature Biotech. 29, 615-624 (2011).
139. Vlahos, R. et al. Neutralizing granulocyte/macrophage colony-stimulating factor inhibits cigarette smoke-induced lung inflammation. Am. J. Respir. Crit. Care Med. 182, 34-40 (2010).
140. Koli, K., Myllarniemi, M., Keski-Oja, J. & Kinnula, V. L. Transforming growth factor-β activation in the lung: focus on fibrosis and reactive oxygen species. Antioxid. Redox. Signal. 10, 333-342 (2008).
141. Soltani, A. et al. Vessel-Associated transforming growth factor-β1 (TGF-β1) is increased in the bronchial reticular basement membrane in COPD and normal smokers. PLoS ONE 7, e39736 (2012).
142. Leung, S. Y. et al. Effect of transforming growth factor-β receptor I kinase inhibitor 2, 4-disubstituted pteridine (SD-208) in chronic allergic airway inflammation and remodeling. J. Pharmacol. Exp. Ther. 319, 586-594 (2006).
143. Woodruff, P. G. et al. Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948BS) in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 181, 438-445 (2010).
144. Chang, L. Y. et al. A catalytic antioxidant attenuates alveolar structural remodeling in bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med. 167, 57-64 (2003).
145. Cheng, Y. F. et al. Pharmacokinetics of 8-hour intravenous infusion of NXY-059: a phase I, randomized, double-blind (within dose panels), placebo-controlled study in healthy Chinese volunteers. Clin. Ther. 30, 2342-2353 (2008).
146. Borbely, G. et al. Small-molecule inhibitors of NADPH oxidase 4. J. Med. Chem. 53, 6758-6762 (2010).
147. Churg, A. et al. Late intervention with a myeloperoxi dase inhibitor stops progression of experimental COPD. Am. J. Respir. Crit. Care Med. 185, 34-43 (2012).
148. Pergola, P. E. et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med. 365, 327-336 (2011).
149. Kappos, L. et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372, 1463-1472 (2008).
150. Tudhope, S. J. et al. Different mitogen-Activated protein kinase-dependent cytokine responses in cells of the monocyte lineage. J. Pharmacol. Exp. Ther. 324, 306-312 (2008). (Pubitemid 350294173)
151. Di Stefano, A. et al. STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. Eur. Resp. J. 24, 78-85 (2004). (Pubitemid 39029072)
152. Qu, P. et al. Stat3 downstream genes serve as biomarkers in human lung carcinomas and chronic obstructive pulmonary disease. Lung Cancer 63, 341-347 (2009).
153. Verstovsek, S. et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366, 799-807 (2012).
154. Sandborn, W. J. et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 367, 616-624 (2012).
155. van Vollenhoven, R. F. et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367, 508-519 (2012).
156. Caramori, G. et al. Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax 58, 348-351 (2003). (Pubitemid 36411423)
157. Weinblatt, M. E. et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 363, 1303-1312 (2010).
158. de Rooij, M. F. et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor-And chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 11 9, 2590-2594 (2012).